Overview

Effects of Phenylephrine on Nasal Congestion in Participants With Seasonal Allergic Rhinitis (P08156 AM2)(Completed)

Status:
Completed
Trial end date:
2011-06-01
Target enrollment:
Participant gender:
Summary
The trial will evaluate the nasal congestion symptom relief of the approved 10 mg phenylephrine (PE) dose and the higher 20 mg, 30 mg, and 40 mg PE doses compared with placebo in participants with histories of seasonal allergic rhinitis, using loratadine as background medication.
Phase:
Phase 2
Details
Lead Sponsor:
Bayer
Treatments:
Loratadine
Oxymetazoline
Phenylephrine